Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Oxidative stress pathways in noncancerous human liver tissue to predict hepatocellular carcinoma recurrence: a prospective, multicenter study.

Tanaka S, Mogushi K, Yasen M, Ban D, Noguchi N, Irie T, Kudo A, Nakamura N, Tanaka H, Yamamoto M, Kokudo N, Takayama T, Kawasaki S, Sakamoto M, Arii S.

Hepatology. 2011 Oct;54(4):1273-81. doi: 10.1002/hep.24536.

PMID:
22006857
2.

Molecular prediction of early recurrence after resection of hepatocellular carcinoma.

Yoshioka S, Takemasa I, Nagano H, Kittaka N, Noda T, Wada H, Kobayashi S, Marubashi S, Takeda Y, Umeshita K, Dono K, Matsubara K, Monden M.

Eur J Cancer. 2009 Mar;45(5):881-9. doi: 10.1016/j.ejca.2008.12.019. Epub 2009 Jan 23.

PMID:
19167881
3.

Surgical contribution to recurrence-free survival in patients with macrovascular-invasion-negative hepatocellular carcinoma.

Tanaka S, Mogushi K, Yasen M, Noguchi N, Kudo A, Kurokawa T, Nakamura N, Inazawa J, Tanaka H, Arii S.

J Am Coll Surg. 2009 Mar;208(3):368-74. doi: 10.1016/j.jamcollsurg.2008.10.031.

PMID:
19317998
4.

Association of mortalin (HSPA9) with liver cancer metastasis and prediction for early tumor recurrence.

Yi X, Luk JM, Lee NP, Peng J, Leng X, Guan XY, Lau GK, Beretta L, Fan ST.

Mol Cell Proteomics. 2008 Feb;7(2):315-25. Epub 2007 Oct 14.

5.

Claudin-10 expression level is associated with recurrence of primary hepatocellular carcinoma.

Cheung ST, Leung KL, Ip YC, Chen X, Fong DY, Ng IO, Fan ST, So S.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):551-6.

6.

Predictive value of expression and promoter hypermethylation of XAF1 in hepatitis B virus-associated hepatocellular carcinoma treated with transplantation.

Zhang F, Wu LM, Zhou L, Chen QX, Xie HY, Feng XW, Zheng SS.

Ann Surg Oncol. 2008 Dec;15(12):3494-502. doi: 10.1245/s10434-008-0146-1. Epub 2008 Oct 2.

PMID:
18830757
7.

Mitochondrial metabolism in the noncancerous liver determine the occurrence of hepatocellular carcinoma: a prospective study.

Kudo A, Mogushi K, Takayama T, Matsumura S, Ban D, Irie T, Ochiai T, Nakamura N, Tanaka H, Anzai N, Sakamoto M, Tanaka S, Arii S.

J Gastroenterol. 2014 Mar;49(3):502-10. doi: 10.1007/s00535-013-0791-4. Epub 2013 Mar 30.

PMID:
23543312
8.

Transcript AA454543 is a novel prognostic marker for hepatocellular carcinoma after curative partial hepatectomy.

Cheung ST, Ho JC, Leung KL, Chen X, Fong DY, So S, Fan ST.

Neoplasia. 2005 Feb;7(2):91-8.

9.

Expression of E-cadherin and vascular endothelial growth factor in noncancerous liver is associated with recurrence of hepatocellular carcinoma after curative resection.

Minata M, Kudo M, Harada KH, Ikai I, Nishida N.

Oncology. 2013;84 Suppl 1:88-92. doi: 10.1159/000345896. Epub 2013 Feb 20.

PMID:
23428865
10.

LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma.

Yang H, Xiong FX, Lin M, Yang Y, Nie X, Zhou RL.

J Cancer Res Clin Oncol. 2010 Feb;136(2):275-81. doi: 10.1007/s00432-009-0659-4. Epub 2009 Aug 19.

PMID:
19690886
11.

Molecular signatures of noncancerous liver tissue can predict the risk for late recurrence of hepatocellular carcinoma.

Utsunomiya T, Shimada M, Imura S, Morine Y, Ikemoto T, Mori M.

J Gastroenterol. 2010 Feb;45(2):146-52. doi: 10.1007/s00535-009-0164-1. Epub 2009 Dec 8. Review.

PMID:
19997856
12.

Liver transplantation and recurrent hepatocellular carcinoma: predictive value of nodule size in a retrospective and explant study.

Grasso A, Stigliano R, Morisco F, Martines H, Quaglia A, Dhillon AP, Patch D, Davidson BR, Rolles K, Burroughs AK.

Transplantation. 2006 Jun 15;81(11):1532-41.

PMID:
16770242
13.

Specific gene-expression profiles of noncancerous liver tissue predict the risk for multicentric occurrence of hepatocellular carcinoma in hepatitis C virus-positive patients.

Okamoto M, Utsunomiya T, Wakiyama S, Hashimoto M, Fukuzawa K, Ezaki T, Hanai T, Inoue H, Mori M.

Ann Surg Oncol. 2006 Jul;13(7):947-54. Epub 2006 May 23.

PMID:
16788756
14.

Clinicopathological risk factors for recurrence within one year after initial hepatectomy for hepatocellular carcinoma.

Hayashi M, Shimizu T, Hirokawa F, Inoue Y, Komeda K, Asakuma M, Miyamoto Y, Takeshita A, Shibayama Y, Tanigawa N.

Am Surg. 2011 May;77(5):572-8.

PMID:
21679590
15.

Association of CYP1A2 genetic polymorphisms with hepatocellular carcinoma susceptibility: a case-control study in a high-risk region of China.

Chen X, Wang H, Xie W, Liang R, Wei Z, Zhi L, Zhang X, Hao B, Zhong S, Zhou G, Zhang L, Gao X, Zhu Y, He F.

Pharmacogenet Genomics. 2006 Mar;16(3):219-27.

PMID:
16495781
16.

Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma.

Woo HG, Park ES, Cheon JH, Kim JH, Lee JS, Park BJ, Kim W, Park SC, Chung YJ, Kim BG, Yoon JH, Lee HS, Kim CY, Yi NJ, Suh KS, Lee KU, Chu IS, Roskams T, Thorgeirsson SS, Kim YJ.

Clin Cancer Res. 2008 Apr 1;14(7):2056-64. doi: 10.1158/1078-0432.CCR-07-1473.

17.

Importin-α1 as a novel prognostic target for hepatocellular carcinoma.

Yoshitake K, Tanaka S, Mogushi K, Aihara A, Murakata A, Matsumura S, Mitsunori Y, Yasen M, Ban D, Noguchi N, Irie T, Kudo A, Nakamura N, Tanaka H, Arii S.

Ann Surg Oncol. 2011 Jul;18(7):2093-103. doi: 10.1245/s10434-011-1569-7. Epub 2011 Feb 1.

PMID:
21286940
18.

Down-regulation of growth arrest DNA damage-inducible gene 45beta expression is associated with human hepatocellular carcinoma.

Qiu W, David D, Zhou B, Chu PG, Zhang B, Wu M, Xiao J, Han T, Zhu Z, Wang T, Liu X, Lopez R, Frankel P, Jong A, Yen Y.

Am J Pathol. 2003 Jun;162(6):1961-74.

19.

CpG island methylator phenotype associated with tumor recurrence in tumor-node-metastasis stage I hepatocellular carcinoma.

Li B, Liu W, Wang L, Li M, Wang J, Huang L, Huang P, Yuan Y.

Ann Surg Oncol. 2010 Jul;17(7):1917-26. doi: 10.1245/s10434-010-0921-7. Epub 2010 Jan 29.

PMID:
20112070

Supplemental Content

Support Center